Blanchard Cheryl R 4
4 · Anika Therapeutics, Inc. · Filed Mar 13, 2025
Insider Transaction Report
Form 4
Blanchard Cheryl R
DirectorPresident, CEO, Director
Transactions
- Exercise/Conversion
Common Stock
2025-03-11+30,060→ 197,015 total - Tax Payment
Common Stock
2025-03-11$16.79/sh−12,675$212,813→ 184,340 total - Exercise/Conversion
Restricted Stock Unit
2025-03-11−30,060→ 0 totalExercise: $0.00→ Common Stock (30,060 underlying)
Holdings
- 11,742(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]Reflects the third and final vesting installment of RSUs granted on March 11, 2022.
- [F2]Reflects an aggregate of 12,675 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2025.
- [F3]Reflects the closing price of ANIK common stock on March 11, 2025, the trading day to which the vesting of RSUs gave rise to tax withholding obligations.
- [F4]Consists of shares transferred by Dr. Blanchard to The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which Dr. Blanchard is a beneficiary and the sole trustee.
- [F5]Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023.